{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:46Z","timestamp":1790007286631,"version":"4.0.1"},"reference-count":94,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-Hodgkin lymphoma\u2019s (NHL) incidence is rising over time, and B cell lymphomas comprise the majority of lymphomas. The phosphoinositide 3-kinase (PI3K)\/v-akt murine thymoma viral oncogene homologue 1 (Akt)\/mammalian target of the rapamycin (mTOR) signaling pathway plays a critical role in a variety of cellular processes, such as cell proliferation and survival. Its role in lymphomagenesis is confirmed in many different types of B cell lymphomas. This review is mainly focused on the PI3K\/v-akt\/mTOR pathway-related oncogenic mechanisms in B cell NHLs with an emphasis on common B cell lymphoma types [diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)]. Furthermore, it summarizes the literature regarding the clinical applications of the mTOR inhibitors temsirolimus and everolimus in B cell NHLs, which have been tested in a range of clinical trials enrolling patients with B cell malignancies, either as monotherapy or in combination with other agents or regimens.<\/jats:p>","DOI":"10.3390\/ijms241814110","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T02:54:13Z","timestamp":1694746453000},"page":"14110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects"],"prefix":"10.3390","volume":"24","author":[{"given":"Eleni A.","family":"Karatrasoglou","sequence":"first","affiliation":[{"name":"First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-9895","authenticated-orcid":false,"given":"Maria","family":"Dimou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Piperidou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Lakiotaki","sequence":"additional","affiliation":[{"name":"First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1883-3898","authenticated-orcid":false,"given":"Penelope","family":"Korkolopoulou","sequence":"additional","affiliation":[{"name":"First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 15773 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1059914","DOI":"10.3389\/fonc.2023.1059914","article-title":"The Epidemiological Patterns of Non-Hodgkin Lymphoma: Global Estimates of Disease Burden, Risk Factors, and Temporal Trends","volume":"13","author":"Chu","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-981-15-3532-1_12","article-title":"B Cell Lymphoma","volume":"1254","author":"Meng","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21252","DOI":"10.1038\/srep21252","article-title":"Potential Role of AKT\/MTOR Signalling Proteins in Hairy Cell Leukaemia: Association with BRAF\/ERK Activation and Clinical Outcome","volume":"6","author":"Lakiotaki","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in Oncogenic Cellular Transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in Lymphocyte Development, Differentiation and Activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31059","DOI":"10.1074\/jbc.M113.508234","article-title":"P87 and P101 Subunits Are Distinct Regulators Determining Class IB Phosphoinositide 3-Kinase (PI3K) Specificity","volume":"288","author":"Shymanets","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1073\/pnas.0509939103","article-title":"PTEN Negatively Regulates Neural Stem Cell Self-Renewal by Modulating G0-G1 Cell Cycle Entry","volume":"103","author":"Groszer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13035","article-title":"Haematopoietic Stem Cells Require a Highly Regulated Protein Synthesis Rate","volume":"509","author":"Signer","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/MTOR Pathway Inhibitors in Lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by Protein Kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0960-9822(99)80265-6","article-title":"Induction of NF-KappaB by the Akt\/PKB Kinase","volume":"9","author":"Kane","year":"1999","journal-title":"Curr. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood.V96.13.4319","article-title":"Nucleophosmin\u2013Anaplastic Lymphoma Kinase Associated with Anaplastic Large-Cell Lymphoma Activates the Phosphatidylinositol 3-Kinase\/Akt Antiapoptotic Signaling Pathway","volume":"96","author":"Bai","year":"2000","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1128\/MCB.21.17.5797-5805.2001","article-title":"C-Myb Transcription Is Activated by Protein Kinase B (PKB) Following Interleukin 2 Stimulation of Tcells and Is Required for PKB-Mediated Protection from Apoptosis","volume":"21","author":"Lauder","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic Sequelae of Interleukin-6 Induced PI3-K\/Akt Signaling in Multiple Myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.169.7.3637","article-title":"IL-12 Provides Proliferation and Survival Signals to Murine CD4+ T Cells through Phosphatidylinositol 3-Kinase\/Akt Signaling Pathway","volume":"169","author":"Yoo","year":"2002","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1074-7613(00)80388-X","article-title":"Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F","volume":"7","author":"Brennan","year":"1997","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Hatfield, K.J., Gr\u00f8nnings\u00e6ter, I.S., and Reikvam, H. (2020). The PI3K-Akt-MTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082907"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.2337\/diabetes.53.11.2748","article-title":"Regulation of Peroxisome Proliferator-Activated Receptor-Gamma Activity by Mammalian Target of Rapamycin and Amino Acids in Adipogenesis","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR Complex 2 Controls the Actin Cytoskeleton and Is Rapamycin Insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1074\/jbc.M112.399485","article-title":"Mutations in Critical Domains Confer the Human MTOR Gene Strong Tumorigenicity","volume":"288","author":"Murugan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.stem.2012.05.026","article-title":"Temporal Changes in PTEN and MTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression","volume":"11","author":"Magee","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.stem.2012.06.009","article-title":"MTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis","volume":"11","author":"Kalaitzidis","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_25","first-page":"285","article-title":"The Inducible Expression of the Tumor Suppressor Gene PTEN Promotes Apoptosis and Decreases Cell Size by Inhibiting the PI3K\/Akt Pathway in Jurkat T Cells","volume":"13","author":"Xu","year":"2002","journal-title":"Cell Growth Differ."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma","volume":"17","author":"Yu","year":"2008","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-Mediated Constitutive PI3K Signaling Limits the Efficacy of P110\u03b4-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"{PTEN Loss in the Continuum of Common Cancers, Rare Syndromes and Mouse Models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA Mutations Are Mutually Exclusive with PTEN Loss in Diffuse Large B-Cell Lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN Loss Defines a PI3K\/AKT Pathway-Dependent Germinal Center Subtype of Diffuse Large B-Cell Lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3109\/10428194.2010.502584","article-title":"PTEN Tumor Suppressor Plays Less Prognostic Role than P53 Tumor Suppressor in Diffuse Large B-Cell Lymphoma","volume":"51","author":"Liu","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yahiaoui, O.I., Nun\u00e8s, J.A., Castanier, C., Devillier, R., Broussais, F., Fabre, A.J., Naimi, D., Bouabdallah, R., Olive, D., and Xerri, L. (2014). Constitutive AKT Activation in Follicular Lymphoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-565"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular Subtypes of Diffuse Large B-Cell Lymphoma Arise by Distinct Genetic Pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The Genetic Landscape of Mutations in Burkitt Lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood.V106.11.4808.4808","article-title":"Role of Phosphatidylinositol 3- Kinase\/AKT Pathway in Diffuse Large B-Cell Lymphoma Survival","volume":"106","author":"Uddin","year":"2005","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","article-title":"Mammalian Target of Rapamycin Inhibition Induces Cell Cycle Arrest in Diffuse Large B Cell Lymphoma (DLBCL) Cells and Sensitises DLBCL Cells to Rituximab","volume":"134","author":"Wanner","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428190500159944","article-title":"Expression of Akt (Protein Kinase B) and Its Isoforms in Malignant Lymphomas","volume":"46","author":"Fillmore","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4161\/cc.26575","article-title":"PI3K\/AKT Addiction in Subsets of Diffuse Large B-Cell Lymphoma","volume":"12","author":"Pfeifer","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/asheducation.V2012.1.402.3798516","article-title":"Paramount Prognostic Factors That Guide Therapeutic Strategies in Diffuse Large B-Cell Lymphoma","volume":"2012","author":"Sehn","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive Nuclear Factor KappaB Activity Is Required for Survival of Activated B Cell-like Diffuse Large B Cell Lymphoma Cells","volume":"194","author":"Brown","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","article-title":"Inhibitors of B-Cell Receptor Signaling for Patients with B-Cell Malignancies","volume":"18","author":"Choi","year":"2012","journal-title":"Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tarantelli, C., Lupia, A., Stathis, A., and Bertoni, F. (2020). Is There a Role for Dual PI3K\/MTOR Inhibitors for Patients Affected with Lymphoma?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031060"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic Heterogeneity of Diffuse Large B-Cell Lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-KappaB Is a Target of AKT in Anti-Apoptotic PDGF Signalling","volume":"401","author":"Romashkova","year":"1999","journal-title":"Nature"},{"key":"ref_48","first-page":"2194","article-title":"Role of Phosphatidylinositol 3-Kinase-Akt Pathway in Nucleophosmin\/Anaplastic Lymphoma Kinase-Mediated Lymphomagenesis","volume":"61","author":"Slupianek","year":"2001","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/Cyclin D1 Gene Overexpression in Chronic Lymphoproliferative Disorders: A Highly Specific Marker of Mantle Cell Lymphoma","volume":"84","author":"Bosch","year":"1994","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm762","article-title":"Cytoplasmic Relocalization and Inhibition of the Cyclin-Dependent Kinase Inhibitor P27(Kip1) by PKB\/Akt-Mediated Phosphorylation in Breast Cancer","volume":"8","author":"Viglietto","year":"2002","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","article-title":"Glycogen Synthase Kinase-3beta Regulates Cyclin D1 Proteolysis and Subcellular Localization","volume":"12","author":"Diehl","year":"1998","journal-title":"Genes Dev."},{"key":"ref_52","first-page":"8226","article-title":"The Molecular Signature of Mantle Cell Lymphoma Reveals Multiple Signals Favoring Cell Survival","volume":"63","author":"Camacho","year":"2003","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene Expression Profiling of Mantle Cell Lymphoma Cells Reveals Aberrant Expression of Genes from the PI3K-AKT, WNT and TGFbeta Signalling Pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_54","first-page":"1433","article-title":"Inhibition of the Mammalian Target of Rapamycin and the Induction of Cell Cycle Arrest in Mantle Cell Lymphoma Cells","volume":"90","author":"Hipp","year":"2005","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II Trial of the Oral MTOR Inhibitor Everolimus in Relapsed Hodgkin Lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Chatzidimitriou, C., Asimakopoulos, J.V., Arapaki, M., Tzoras, E., Angelopoulou, M.K., and Konstantopoulos, K. (2019). Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers, 11.","DOI":"10.3390\/cancers11081071"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"204062072090291","DOI":"10.1177\/2040620720902911","article-title":"Optimizing Outcomes in Relapsed\/Refractory Hodgkin Lymphoma: A Review of Current and Forthcoming Therapeutic Strategies","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase 2 Trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III Study to Evaluate Temsirolimus Compared with Investigator\u2019s Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10428194.2017.1357175","article-title":"Comparison of Two Doses of Intravenous Temsirolimus in Patients with Relapsed\/Refractory Mantle Cell Lymphoma","volume":"59","author":"Jurczak","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus Temsirolimus in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: An International, Randomised, Open-Label, Phase 3 Study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus Temsirolimus: 3-Year Follow-up of Patients with Previously Treated Mantle Cell Lymphoma from the Phase 3, International, Randomized, Open-Label RAY Study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Phase 2 Study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00277-020-04159-3","article-title":"Safety and Efficacy of Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the LYSA","volume":"99","author":"Tessoulin","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/HS9.0000000000000398","article-title":"Final Results of a Phase I\/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma","volume":"4","author":"Hess","year":"2020","journal-title":"HemaSphere"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/cncr.29502","article-title":"A Phase 2 Study of Weekly Temsirolimus and Bortezomib for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdu273","article-title":"Phase I Trial of Rituximab, Cladribine, and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma","volume":"25","author":"Inwards","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A Phase II Trial of the Oral MTOR Inhibitor Everolimus in Relapsed Aggressive Lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A Multicenter Phase II Trial (SAKK 36\/06) of Single-Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjh.12780","article-title":"Everolimus for Patients with Mantle Cell Lymphoma Refractory to or Intolerant of Bortezomib: Multicentre, Single-Arm, Phase 2 Study","volume":"165","author":"Wang","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin\u2019s Lymphoma Subtypes: The University of Chicago Phase II Consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter Phase II Study of Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","article-title":"Patients with Chemotherapy-Refractory Mantle Cell Lymphoma Experience High Response Rates and Identical Progression-Free Survivals Compared with Patients with Relapsed Disease Following Treatment with Single Agent Bortezomib: Results of a Multicentre Phas","volume":"145","author":"Moskowitz","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a Phase 2 Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma","volume":"115","author":"Taetle","year":"2010","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II Trial of Temsirolimus for Relapsed\/Refractory Primary CNS Lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2012.075184","article-title":"Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma","volume":"98","author":"Barnes","year":"2013","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2018.06.013","article-title":"A Novel Combination of the MTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma","volume":"18","author":"Padrnos","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/07357907.2021.1983584","article-title":"Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"39","author":"Islam","year":"2021","journal-title":"Cancer Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.clml.2020.02.006","article-title":"A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed\/Refractory Lymphoid Hematologic Malignancies","volume":"20","author":"Hoeg","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus Combined with R-CHOP-21 for New, Untreated, Diffuse Large B-Cell Lymphoma (NCCTG 1085 [Alliance]): Safety and Efficacy Results of a Phase 1 and Feasibility Trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1038\/bcj.2017.57","article-title":"High Rate of Event-Free Survival at 24 Months with Everolimus\/RCHOP for Untreated Diffuse Large B-Cell Lymphoma: Updated Results from NCCTG N1085 (Alliance)","volume":"7","author":"Witzig","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood.V128.22.3034.3034","article-title":"Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials","volume":"128","author":"Maurer","year":"2016","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdx764","article-title":"Adjuvant Everolimus in High-Risk Diffuse Large B-Cell Lymphoma: Final Results from the PILLAR-2 Randomized Phase III Trial","volume":"29","author":"Witzig","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical Activity of Everolimus in Relapsed\/Refractory Marginal Zone B-Cell Lymphomas: Results of a Phase II Study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ajh.24671","article-title":"Efficacy of the Oral MTORC1 Inhibitor Everolimus in Relapsed or Refractory Indolent Lymphoma","volume":"92","author":"Bennani","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle Cell Lymphoma-Update on Molecular Biology, Prognostication and Treatment Approaches","volume":"1","author":"Silkenstedt","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Papageorgiou, S., Pashley, S.L., O\u2019Regan, L., Khan, S., Bayliss, R., and Fry, A.M. (2022). Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers, 14.","DOI":"10.3390\/cancers14143452"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"599561","DOI":"10.3389\/fphar.2021.599561","article-title":"Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin\u2019s Disease","volume":"12","author":"Luke","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","article-title":"mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta\/delta blockage in diffuse large B-cell lymphoma","volume":"37","author":"Xu","year":"2023","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:51:02Z","timestamp":1760129462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":94,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241814110"],"URL":"https:\/\/doi.org\/10.3390\/ijms241814110","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}